Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.41

€0.41

-1.970%
-0.0082
-1.970%
€19.13
 
11.04.24 / Tradegate WKN: A1JLKZ / Symbol: AGEN / Name: Agenus / Stock / Biotechnology & Medical Research / Small Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Description Agenus

Agenus Inc. (AGEN) is a biotechnology company that focuses on the development and commercialization of immuno-oncology therapeutics for the treatment of cancer. The company's pipeline includes a range of checkpoint modulators, vaccines, and adjuvants designed to activate immune response mechanisms against cancer.

The company’s products include Prophage series of cancer vaccines, Oncophage, Agenus CPM Series vaccine adjuvants, QS-21 Stimulon adjuvant, and AS-15 Immunologic adjuvant, among others.

Agenus was founded in 1994 and is headquartered in Lexington, Massachusetts. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN. Its market capitalization, as of September 2021, was approximately $1.9 billion.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Agenus Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Agenus

sharewise wants to provide you with the best news and tools for Agenus, so we directly link to the best financial data sources.

News

Agenus (AGEN) Q4 2024 Earnings Call Transcript
Agenus (AGEN) Q4 2024 Earnings Call Transcript

Image source: The Motley Fool.

Agenus (NASDAQ: AGEN)Q4 2024 Earnings CallMar 11, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com